Login Register Cart 0
Generic placeholder image

Infectious Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5265
ISSN (Online): 2212-3989

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Naloxone Effects Against Cutaneous Leishmaniasis Caused by Leishmania major Strain MRHO/IR/75/ER in the BALB/c Mice

Author(s): Hakim Azizi*, Elham Mahdavinik, Maryam Hataminejad, Ali Khamesipour and Sareh Montazeri

Volume 23, Issue 6, 2023

Published on: 06 July, 2023

Article ID: e020623217598 Pages: 5

DOI: 10.2174/1871526523666230602113613

Price: $65

Abstract

Introduction: Cutaneous leishmaniasis (CL) is a serious health problem in some parts of the world, such as Iran. Since the use of pentavalent antimonial compounds such as meglumine antimoniate (Glucantime, MA) for the treatment of CL has side effects, naloxone as a new treatment in the footpad of Leishmania major (L. major)-infected BALB/c mice was investigated by evaluating the lesion size and the parasite burden.

Method: The animals were infected with L. major (MRHO/IR/75/ER). 40 BALB/c mice were divided into 4 groups (10/group), and were treated as follows 39 days after L. major infection: Group 1 treated with intraperitoneal injections of MA (100 mg/kg, positive control group) daily for six weeks; Group 2 received a 100 μl injection of PBS (negative control group); Group 3 received subcutaneous (SC) injections of naloxone (10 mg/kg) daily for six weeks (Naloxone1), and Group 4 was SC injected with naloxone (10 mg/kg) weekly for six weeks (Naloxone2). The lesion size was measured using a digital caliper.

Result: After the end of treatment, the lesion parasite burden was evaluated. As compared to the negative control group, the groups that received MA and naloxone (groups 1, 3, and 4) showed fewer parasites. Also, the naloxone-treated mice showed significantly smaller lesion sizes than the negative control group (p˂0.05), but they did not differ significantly from the MA-treated mice.

Conclusion: Taken together, the results suggest that naloxone might be a promising and alternative treatment for CL.

Graphical Abstract

[1]
Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, Brooker S. Cutaneous leishmaniasis. Lancet Infect Dis 2007; 7(9): 581-96.
[http://dx.doi.org/10.1016/S1473-3099(07)70209-8] [PMID: 17714672]
[2]
Aoun K, Bouratbine A. Cutaneous leishmaniasis in North Africa: A review. Parasite 2014; 21: 14.
[http://dx.doi.org/10.1051/parasite/2014014] [PMID: 24626301]
[3]
Bessat M, Okpanma A, Shanat E. Leishmaniasis: Epidemiology, control and future perspectives with special emphasis on Egypt. J Trop Dis 2015; 2(153): 1-10.
[4]
Khamesipour A. Therapeutic vaccines for leishmaniasis. Expert Opin Biol Ther 2014; 14(11): 1641-9.
[http://dx.doi.org/10.1517/14712598.2014.945415] [PMID: 25077737]
[5]
Salam N, Al-Shaqha WM, Azzi A. Leishmaniasis in the middle East: Incidence and epidemiology. PLoS Negl Trop Dis 2014; 8(10): e3208.
[http://dx.doi.org/10.1371/journal.pntd.0003208] [PMID: 25275483]
[6]
McGwire BS, Satoskar AR. Leishmaniasis: Clinical syndromes and treatment. QJM 2014; 107(1): 7-14.
[http://dx.doi.org/10.1093/qjmed/hct116] [PMID: 23744570]
[7]
Dowlati Y. Cutaneous leishmaniasis. Clin Dermatol 1996; 14(5): 425-31.
[http://dx.doi.org/10.1016/0738-081X(96)00058-2] [PMID: 8889320]
[8]
Croft SL, Coombs GH. Leishmaniasis- current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol 2003; 19(11): 502-8.
[http://dx.doi.org/10.1016/j.pt.2003.09.008] [PMID: 14580961]
[9]
Kato KC, Morais-Teixeira E, Reis PG, et al. Hepatotoxicity of pentavalent antimonial drug: Possible role of residual Sb(III) and protective effect of ascorbic acid. Antimicrob Agents Chemother 2014; 58(1): 481-8.
[http://dx.doi.org/10.1128/AAC.01499-13] [PMID: 24189251]
[10]
Sacks D, Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2002; 2(11): 845-58.
[http://dx.doi.org/10.1038/nri933] [PMID: 12415308]
[11]
Burris S, Norland J, Edlin BR. Legal aspects of providing naloxone to heroin users in the United States. Int J Drug Policy 2001; 12(3): 237-48.
[http://dx.doi.org/10.1016/S0955-3959(01)00080-9]
[12]
McCarthy L, Wetzel M, Sliker JK, Eisenstein TK, Rogers TJ. Opioids, opioid receptors, and the immune response. Drug Alcohol Depend 2001; 62(2): 111-23.
[http://dx.doi.org/10.1016/S0376-8716(00)00181-2] [PMID: 11245967]
[13]
Panerai A, Manfredi B, Granucci F, Sacerdote P. The β-endorphin inhibition of mitogen-induced splenocytes proliferation is mediated by central and peripheral paracrine/autocrine effects of the opioid. J Neuroimmunol 1995; 58(1): 71-6.
[http://dx.doi.org/10.1016/0165-5728(94)00189-U] [PMID: 7537282]
[14]
Molla Hassan AT, Hassan ZM, Moazzeni SM, et al. Naloxone can improve the anti-tumor immunity by reducing the CD4+CD25+Foxp3+ regulatory T cells in BALB/c mice. Int Immunopharmacol 2009; 9(12): 1381-6.
[http://dx.doi.org/10.1016/j.intimp.2009.08.008] [PMID: 19706340]
[15]
Sacerdote P, Gaspani L, Panerai A. The opioid antagonist naloxone induces a shift from type 2 to type 1 cytokine pattern in normal and skin-grafted mice. Ann N Y Acad Sci 2000; 917(1): 755-63.
[http://dx.doi.org/10.1111/j.1749-6632.2000.tb05440.x] [PMID: 11268404]
[16]
Müller I, Fruth U, Louis JA. Immunobiology of experimental leishmaniasis. Med Microbiol Immunol 1992; 181(1): 1-12.
[http://dx.doi.org/10.1007/BF00193391] [PMID: 1349724]
[17]
Howard JG, Hale C, Chan-Liew WL. Immunological regulation of experimental cutaneous leishmaniasis. Immunogenetic aspects of susceptibility to Leishmania tvopica in mice. Parasite Immunol 1980; 2(4): 303-14.
[http://dx.doi.org/10.1111/j.1365-3024.1980.tb00061.x] [PMID: 7220075]
[18]
Jaafari MR, Hatamipour M, Alavizadeh SH, et al. Development of a topical liposomal formulation of Amphotericin B for the treatment of cutaneous leishmaniasis. Int J Parasitol Drugs Drug Resist 2019; 11: 156-65.
[http://dx.doi.org/10.1016/j.ijpddr.2019.09.004] [PMID: 31582344]
[19]
Lohoff M, Ferrick D, Mittrücker HW, et al. Interferon regulatory factor-1 is required for a T helper 1 immune response in vivo. Immunity 1997; 6(6): 681-9.
[http://dx.doi.org/10.1016/S1074-7613(00)80444-6] [PMID: 9208841]
[20]
Titus RG, Marchand M, Boon T, Louis JA. A limiting dilution assay for quantifying Leishmania major in tissues of infected mice. Parasite Immunol 1985; 7(5): 545-55.
[http://dx.doi.org/10.1111/j.1365-3024.1985.tb00098.x] [PMID: 3877902]
[21]
Alavi-Naini R, Fazaeli A, O’Dempsey T. Topical treatment modalities for old world cutaneous leishmaniasis: A review. Prague Med Rep 2012; 113(2): 105-18.
[http://dx.doi.org/10.14712/23362936.2015.26] [PMID: 22691282]
[22]
Daie Parizi MH, Karvar M, Sharifi I, et al. The topical treatment of anthroponotic cutaneous leishmaniasis with the tincture of thioxolone plus benzoxonium chloride (Thio-Ben) along with cryotherapy: A single-blind randomized clinical trial. Dermatol Ther 2015; 28(3): 140-6.
[http://dx.doi.org/10.1111/dth.12229] [PMID: 25847678]
[23]
Woody GE. Antagonist models for treating persons with substance use disorders. Curr Psychiatry Rep 2014; 16(10): 489.
[http://dx.doi.org/10.1007/s11920-014-0489-1] [PMID: 25182514]
[24]
Mohammadzadeh Hajipirloo H, Bozorgomd A, Shahabi S, Hazrati Tappeh K, Karamati SA. Evaluation of alum-naltrexone adjuvant activity, on efficacy of anti-leishmania immunization with autoclaved leishmania major (MRHO/IR/75/ER) antigens in BALB/C mice. Iran J Parasitol 2014; 9(3): 311-8.
[PMID: 25678914]
[25]
Jazani NH, Karimzad M, Mazloomi E, et al. Evaluation of the adjuvant activity of naloxone, an opioid receptor antagonist, in combination with heat-killed Listeria monocytogenes vaccine. Microbes Infect 2010; 12(5): 382-8.
[http://dx.doi.org/10.1016/j.micinf.2010.02.001] [PMID: 20152926]
[26]
Belosevic M, Finbloom DS, Van Der Meide PH, Slayter MV, Nacy CA. Administration of monoclonal anti-IFN-gamma antibodies in vivo abrogates natural resistance of C3H/HeN mice to infection with Leishmania major. J Immunol 1989; 143(1): 266-74.
[http://dx.doi.org/10.4049/jimmunol.143.1.266] [PMID: 2499629]
[27]
Mitchell GF, Curtis JM, Scollay RG, Handman E. Resistance and abrogation of resistance to cutaneous leishmaniasis in reconstituted BALB/c nude mice. Aust J Exp Biol Med Sci 1981; 59(5): 539-54.
[http://dx.doi.org/10.1038/icb.1981.47] [PMID: 6976781]
[28]
Alimohammadian MH, Riazi-Rad F, Asadi-Tat M, et al. Naloxone diminishes the virulence and modifies the cellular immune responses of BALB/c mice infected with Leishmania major. Acta Parasitol 2021; 66(2): 517-23.
[http://dx.doi.org/10.1007/s11686-020-00308-w] [PMID: 33211271]
[29]
Karaji AG, Hamzavi Y. The opioid antagonist naloxone inhibits Leishmania major infection in BALB/c mice. Exp Parasitol 2012; 130(1): 73-7.
[http://dx.doi.org/10.1016/j.exppara.2011.09.006] [PMID: 22019408]
[30]
Bozorgomid A, Hajipirloo HM, Tappeh KH, Nazari N, Karamati SA, Shirooie S. Evaluation of the alum-naloxone adjuvant activity against experimental murine leishmaniasis due to L. major. J Parasit Dis 2016; 40(4): 1141-5.
[http://dx.doi.org/10.1007/s12639-015-0731-8] [PMID: 27876902]
[31]
Jamali A, Mahdavi M, Hassan ZM, et al. A novel adjuvant, the general opioid antagonist naloxone, elicits a robust cellular immune response for a DNA vaccine. Int Immunol 2009; 21(3): 217-25.
[http://dx.doi.org/10.1093/intimm/dxn139] [PMID: 19174474]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy